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1  | INTRODUC TION
Periodontitis is a set of chronic inflammatory disorders of tissues sur-
rounding the teeth that leads to pocket formation and breakdown of 
alveolar bone around the teeth, resulting in tooth loss.1 Aggressive 
periodontitis is a less common, but more severe, form of the dis-
ease than chronic periodontitis that usually affects younger patients 
and typically manifests as rapid loss of periodontal attachment and 
bone destruction.2,3 The disease is a consequence of accumulation 
of bacteria in dental plaque.3,4 Bacterial components, such as lipo-
polysaccharide (LPS) recognized by toll- like receptors of resident 
cells and inflammatory leukocytes trigger an intracellular signaling 
cascade resulting in the activation of nuclear factor- kappa B, a key 
transcription factor responsible for the expression of many genes in-
volved in inflammation, such as pro- inflammatory cytokines, chemo-
kines, adhesion molecules, and prostaglandins.5-7 Consequently, 
leukocytes migrating to the periodontal tissues disrupt homeostatic 
conditions of these tissues through production of toxic products 
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Background and Objective: MicroRNA- 146a (miR- 146a) is a small noncoding RNA 
that plays a critical role in the negative regulation of the innate immune response, and 
the dysregulation of miR- 146a has been associated with several inflammatory disor-
ders. In generalized aggressive periodontitis (GAgP) the degree of clinical inflamma-
tion appears to be similar to that of chronic periodontitis, and, in this situation, age of 
onset and family history are important additional criteria for diagnosis. This study 
was performed to evaluate the level of miR- 146a expressed in gingival tissues of pa-
tients with GAgP and its association with disease severity.
Material and Methods: Gingival samples from 18 patients with GAgP and 10 healthy 
subjects were collected and the level of miR- 146a and its targets, including necrosis 
factor-alpha, interleukin- 1beta, and interleukin- 6, were assessed using real- time 
PCR.
Clinical parameters, including probing depth and clinical attachment loss, were meas-
ured and their correlations with the level of miR- 146a were determined.
Results: Our results demonstrated an elevation in the level of miR- 146a expressed in 
patients with GAgP compared with healthy controls (P < .001), which was directly 
associated with disease severity (P < .05). Overexpression of miR- 146a was accompa-
nied by a reduction in the levels of pro- inflammatory cytokines.
Conclusions: Our findings suggest that there is an association between miR- 146a and 
GAgP and imply that miR- 146a may serve as an indicator of periodontal disease se-
verity. However, further studies and additional information are required to confirm 
this relationship and the precise role of miR- 146a in the development and/or progres-
sion of periodontitis.
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(such as reactive oxygen and nitrogen species) and enzymes (such 
as matrix metalloproteinases), leading to the destruction of soft tis-
sues.8,9 In addition, alveolar bone loss, a major feature of the disease, 
occurs because of an imbalance of receptor activator of nuclear fac-
tor kappa-Β ligand (RANKL)/osteoprotegerin levels.10,11 Elevation of 
RANKL and reduction of osteoprotegerin shift the balance of osteo-
clastogenesis/osteoblastogenesis to bone resorption.10,11
MicroRNAs (miRNAs) were discovered by Ambros in 1993.12 
They are small noncoding RNAs (about 22 nucleotides in length) that 
contribute to gene regulation by binding to target sites of messen-
ger ribonucleic acid (mRNA).13 This leads to mRNA degradation or 
inhibition of protein translation.13 It appears that > 30% of human 
genes have complementary sites to the seed region of miRNAs (nu-
cleotides 2- 7).14 Therefore, a large number of genes are regulated 
by miRNAs. In addition to physiological involvement of miRNAs in 
a wide range of biological processes, dysregulation of miRNAs has 
been addressed in a number of diseases, including cancers, and 
heart, kidney, and neurological diseases.15-18
The miR- 146 family consists of two evolutionarily conserved mem-
bers, namely miR- 146a and miR- 146b, which are located on different 
chromosomes and for which the mature forms differ by 2 nucleo-
tides.19 In spite of significant structural similarities between miR- 146a 
and miR- 146b, it does not seem that their biological activities are the 
same.19 It has been shown that upon LPS stimulation, the mature form 
of miR- 146a is produced in a nuclear factor- kappa B- dependent man-
ner, leading to negative regulation of the innate immune response via 
the downregulation of pro- inflammatory cytokines, chemokines, and 
other inflammatory mediators.19,20 miR- 146a is a key regulator of LPS 
tolerance.21 LPS tolerance is a phenomenon in which, after prolonged 
exposure to LPS, monocytes develop a hyporesponsiveness state 
to subsequent LPS challenge, leading to the control of intensity and 
duration of inflammation.21 Therefore, we hypothesized that down-
regulation of miR- 146a or its impaired function may be associated 
with diseases, such as aggressive periodontitis, in which sustained 
or exaggerated inflammation contribute to pathogenesis. Herein, we 
assessed the expression level and functional status of miR- 146a in 
generalized aggressive periodontitis (GAgP) to clarify whether there 
is any association between miR- 146a and this form of periodontitis.
2  | MATERIAL AND METHODS
2.1 | Tissue samples and clinical examination
Periodontists collected periodontal samples from 18 patients with 
GAgP (7 male and 11 female subjects, mean age = 27 years) during 
surgical therapy. According to the update of the 1999 American 
academy of periodontology classification criteria for periodontal 
disease,22-24 patients with GAgP are diagnosed based on signifi-
cant and rapid attachment loss and bone destruction in the pres-
ence of low local factors (plaque and calculus) and are usually 
younger than 30 years of age. Except for the periodontits, the 
patients were systemically healthy. In addition, they had general-
ized interproximal attachment loss affecting at least 3 permanent 
teeth other than the first molars and incisors. In these patients, 
>30%	of	sites	involved	had	clinical	attachment	loss	of	≥5	mm	and	
radiographic bone loss of >30%, usually presenting as a vertical 
bone lesion, as well as the presence of bleeding on probing (BOP). 
All clinical parameters were measured using a calibrated Michigan 
O probe with Williams Markings (Hu Friedy, Chicago, IL, USA). Six 
sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, and 
distolingual) were examined for each tooth. For this group, Phase 
I periodontal therapy consisted of supra- and subgingival scaling; 
polishing and oral hygiene instruction was accomplished at least 
1 month before surgery; and periodontal charting and BOP evalu-
ation were performed at the first visit and 1 week before surgery 
to confirm BOP positivity of the site. Exclusion criteria were: any 
known systemic disease; pregnancy and breast feeding; any his-
tory of cigarette smoking, alcohol consumption or drug abuse; any 
history of medication uptake (such as calcium channel blockers, or 
anticonvulsive and immunosuppressive agents) that could affect 
periodontal conditions; any history of allergy; orthodontic ther-
apy; or antibiotic therapy in the preceding 6 months. In addition, 
sampling was not performed around wisdom teeth, teeth with 
heavy occlusal interferences, teeth with combined periodontal- 
endodontal problems, or teeth with pericoronitis and pathologies 
such as ulcers, cysts, abscesses, or tumors.
Tissue samples of 10 healthy subjects (1 male and 9 female sub-
jects, mean age = 32 years) were obtained during crown- lengthening 
surgery with the inclusion criteria probing depth <3 mm, clinical at-
tachment loss <3 mm without any radiographic evidence of alveolar 
bone loss, and no sign of BOP in the operation site at the first visit 
and at the operation session.
At the first visit, all the local irritating factors, including calcu-
lus, bacterial plaque, caries, and unfavorable temporary crowns with 
subgingival margins, were removed and individuals were instructed 
to brush their teeth 3 times a day and to floss once daily, and surgery 
was scheduled for at least 1 week later.
Subjects were included in the study after providing informed 
consent, in accordance with the Ethics Committee of Shahid 
Beheshi University of Medical Sciences, in accordance with the 
Helsinki Declaration of 1975, as revised in 2013.
According to the SD values observed in similar research1,25,26, 
sample sizes for the groups of patients and healthy controls were 
estimated using the following statistical formula:
α (study accuracy) = % 95; β (study power) = % 80; d (effect size) = % 
80; Zα = 1.96; Zβ = 0.84; S1 = 1.2; S2 = 1.
2.2 | Measurement of miR- 146a and  
pro- inflammatory cytokine levels
Total ribonucleic acid (RNA) were isolated from periodontal tissues that 
were	stored	 in	RNAlater	 (Qiagen,	Germantown,	MD,	USA)	at	−20°C	
(mirVana miRNA isolation kit; Ambion, Austin, TX, USA) according to 
n=
(Zα+Zβ)2× (S12+S22)
d
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the manufacturer’s protocol. Tissue samples were homogenized (using 
1.0- mm silicon carbide beads; BioSpec products, Bartlesville, OK, 
USA) before RNA isolation. RNA yield was determined and the purity 
was assessed using a spectrophotometer (NanoDrop 8000 spectro-
photometer; Thermo Fisher Scientific, Wilmington, DE, USA).
For miR-146a, complementary deoxyribonucleic acid (cDNA) 
synthesis was performed by the TaqMan microRNA reverse tran-
scription kit (Ambion). Afterwards, real-time polymerase chian reac-
tion (PCR) was carried out using TaqMan® Universal Master Mix II, 
no UNG, and hsa-miRNA146a kits (Applied Biosystems, Foster City, 
CA, USA) according to the manufacturer’s instructions.
Total RNAs were reverse transcribed to determine the levels of 
pro- inflammatory cytokine genes expressed, including tumor ne-
crosis factor alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 
(IL-6) (RevertAid First Strand cDNA Synthesis Kit; Thermo Fisher 
Scientific) according to the manufacturer’s protocol.
Real- time PCR was performed on a Rotor Gene 6000 (Qiagen, 
Hilden, Germany) in a 15- μL reaction mixture containing 7.5 μL of 
Master Mix (SYBR® Premix Ex Taq™ II; TaKaRa, Kyoto, Japan), 0.5 μL 
of each 10 pM primer, 0.5 μL of cDNA template, and DNase- and 
RNase- free water (6 μL).	 Each	 reaction	was	 incubated	 at	 95°C	 for	
30	seconds	followed	by	40	cycles	of	95°C	for	5	seconds	and	60°C	for	
30 seconds. The melting curve analysis was performed in the tem-
perature	range	from	65°C	to	95°C	at	the	end	of	each	run.	Sequences	
of primers are summarized in Table 1.
Glyceraldehyde- 3- phosphate dehydrogenase (GAPDH) was 
used as an internal control to normalize the expression level of each 
sample (Table 1). The reaction mixtures and cycling parameters for 
GAPDH were the same as those used for the cytokines, with the ex-
ception	of	the	annealing	temperature	(55°C	for	30	seconds).	Relative	
expression of miR- 146a and cytokines were calculated using the 
2−∆∆ct method.27
2.3 | Statistical analysis
Data were analyzed using SPSS software (v.17; SPSS, Chicago, IL, 
USA). The Student’s t test was used to compare gene expression 
between groups with a normal distribution and the Mann- Whitney 
test was used to compare gene expression between groups with a 
non- normal distribution. The correlation study was performed using 
Pearson’s test (in the case of normal distribution) or Spearman’s test 
(in the case of non- normal distribution). A value of P	≤	.05	was	con-
sidered statistically significant.
3  | RESULTS
3.1 | Clinical findings
In order to evaluate disease severity, clinical attachment loss and 
probing depth were measured at disease sites of each study partici-
pant. The diseased sites of patients with GAgP demonstrated sta-
tistically significantly higher probing depth and clinical attachment 
loss values when compared with the sample sites of patients in the 
control group. Despite higher values of both clinical attachment loss 
and probing depth in patients with GAgP, there was no correlation 
between clinical attachment loss and probing depth in these pa-
tients. As analysis using the Kolmogorov- Smirnov test was unable to 
identify any normal distribution of data for either clinical attachment 
loss (P < .03) or probing depth (P < .05), this might explain the lack 
of correlation between clinical attachment loss and probing depth.
The average age of patients was significantly lower than those 
of healthy subjects, suggesting that the younger population has an 
increased risk for aggressive periodontitis. A summary of clinical and 
demographic parameters is given in Table 2.
3.2 | Increased expression of miR- 146a in GAgP and 
its association with disease severity
Considering the role of miR- 146a as a negative- feedback regulator 
of inflammation, we investigated whether any change in the level 
of miR- 146a existed in GAgP. We used real- time PCR to measure 
the miR- 146a level in diseased sites of gingival tissues. We found 
a 17.8- fold elevation in miR- 146a expression in patients compared 
with healthy subjects (P < .001) (Figure 1).
To determine the association between the miR- 146a level and 
disease severity, we performed correlation tests. Patients with 
GAgP who had a higher probing depth score had much more ele-
vated level of miR- 146a expression than those patients with lower 
probing depth (Spearman’s correlation coefficient = 0.504, P < .05) 
(Figure 2). However, no significant association between the miR- 
146a level and clinical attachment loss was observed (P	≈	.17).
3.3 | Decreased expression of TNF- α, IL- 1β, and 
IL- 6 in disease sites in line with the elevated level of 
miR- 146a
To assess the regulatory role of miR- 146a, we monitored its effect 
on the level of pro- inflammatory cytokines expressed. In spite of 
Gene Forward primer (5′- 3′) Reverse primer(5′- 3′)
TNFα GCTGCACTTTGGAGTGATCG GGGTTTGCTACAACATGGGC
IL1β GCACGATGCACCTGTACGAT TGGAGAACACCACTTGTTGC
IL6 CTTCTCCACAAGCGCCTTCG CTGAGATGCCGTCGAGGATG
GAPDH CTCTGGTAAAGTGGATATTG GGTGGAATCATATTGGAACA
Primer sequences for amplification of tumor necrosis factor-alpha (TNF-α), interleukin- 1beta (IL-1β), 
interleukin- 6 (IL-6), and glyceraldehyde- 3- phosphate dehydrogenase (GAPDH) mRNAs in SYBR 
Green- based real- time PCR.
TABLE  1 Sequences of primers for 
real- time PCR
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an established ethologic role of the inflammatory response in the 
pathogenesis of periodontitis, we observed a significant decrease of 
TNF- α, IL- 1β, and IL- 6 compared with healthy control subjects fol-
lowing Phase I periodontal therapy (P	≤	.05)	(Figure	3).
4  | DISCUSSION
miRNAs, which are regulators of gene expression post- transcription, 
play crucial roles in the physiological process.13 Among them, 
miR- 146a serves as a key negative regulator of the innate immune 
response.20 Regarding the implication of miR- 146a in human inflam-
matory disorders owing to its role in the regulation of inflammation, 
we sought to determine whether miR- 146a expression has any po-
tential link to the disease severity in GAgP.
In this study, we evaluated the miR- 146a level in the gingival tis-
sues of patients with aggressive periodontitis. Our results demonstrated 
a massively increased expression of miR- 146a in the periodontal tis-
sues obtained from patients with GAgP during surgical treatment. 
Groups
Probing  
depth (mm)
Clinical 
attachment 
loss (mm)
Age  
(years) Gender
Aggressive  
periodontitis
5.61 ± 1.61 7.10 ± 1.9 27 ± 13 11 female 
subjects
7 male subjects
Healthy  
subjects
2.00 ± 0.45 2.10 ± 0.54 32 ± 12 9 female subjects
1 male subject
Data are shown as mean ± SD.
TABLE  2 Clinical and demographic 
findings
F IGURE  1 Levels of microRNA- 146a (miR- 146a) in gingival 
tissues from patients with GAgP. Subjects with GAgP had a higher 
level of miR- 146a in their gingival tissues compared with subjects in 
the control group. Data are shown as mean ± standard error of the 
mean (SEM) of relative expression of miR- 146a. *P	≤	.05
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F IGURE  2 Association between the level of microRNA- 146a 
(miR- 146a) expressed and clinical parameters in patients with 
generalized aggressive periodontitis (GAgP). Spearman’s correlation 
test showed a positive correlation between the miR- 146a 
expression level and probing depth in patients. *P	≤	.05
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F IGURE  3 Pro- inflammatory cytokine levels in gingival tissues 
from patients with generalized aggressive periodontitis (GAgP). 
Quantification of cytokine levels in gingival tissues of patients 
showed a significant reduction in the levels of tumor necrosis factor 
alpha (TNF- α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). All 
data are shown as mean ± standard error of the mean (SEM) of the 
relative expression of cytokines. *P	≤	.05
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Consistently, we also observed increased expression of miR- 146a in 
patients with the chronic form of periodontitis.1 Of course, given the 
difference in nature of these two diseases, comparison of the results 
is not logical. Subsequently, we evaluated the regulatory role of miR- 
146a in gene expression through assessing the expression of its targets. 
Among them, targets of proteins operating in the signaling of toll- like 
receptors and cytokine receptors (including TNF- α, IL- 1β, and IL- 6) were 
assessed.6,20 According to our findings, overexpression of miR- 146a in 
patients with GAgP was accompanied by a reduction in expression of 
these targets; we also found the same results in chronic periodontitis, 
although this disease is very different from aggressive periodontitis.1 This 
difference may be a result of the regulatory role of miR- 146a on produc-
tion of pro- inflammatory cytokines,13,20 but direct correlations between 
miR- 146a expression and clinical parameters do not support a regulatory 
role of miR- 146. In fact, this suggests that miR- 146a may contribute to 
the pathogenesis of disease and/or serve as an indicator of disease se-
verity in GAgP. Based on the current data, as stated by Takahashi et al27, 
the immunological risk factors in generalized or localized aggressive 
periodontitis vary widely,25,28-31 so by considering the expression of only 
a few cytokines we cannot conclude that in GAgP there is a reduction 
in expression of pro- inflammatory cytokines; in addition, the mRNA of 
some inflammatory cytokines, such as TNF- α, has a very short half life.31
It also has been shown that in response to inflammatory cytokines 
and bacterial components, such as LPS, miR- 146a is upregulated in 
monocytes.20 miR- 146a, in turn, contributes to the downregulation of 
IL- 1 receptor- associated kinase- 1 and tumor necrosis factor receptor- 
associated factor 6, which are adaptor proteins operating downstream 
of toll- like receptors and cytokine receptors.20 This leads to abolished 
activation of nuclear factor- kappa B, a key transcription factor implicated 
in transcription of many genes involved in inflammation, such as TNFα, 
IL-1β, IL-6, and IL-8, and chemokines, adhesion molecules, and prosta-
glandins.6 We hypothesize that in aggressive periodontitis, bacterial com-
ponents of plaque, particularly LPS, stimulate toll- like receptors, leading 
to elevation of the miR- 146a level, which subsequently controls the level 
of pro- inflammatory cytokines through a negative- feedback loop.
Given the essential role of inflammation in the pathogenesis of 
periodontitis,34 the unexpected finding of decreased expression of 
TNF- α, IL- 1β, and IL- 6, which are major pro- inflammatory cytokines, 
points to the contribution of other inflammatory mediators and/or 
a nonimmunologic- dependent mechanism in progression of the dis-
ease following Phase I periodontal therapy.
On other hand, it was shown that miR- 146a participates in the 
regulation of many genes; for instance, downregulation of epidermal 
growth factor receptor and transforming growth factor beta;33-35 so, 
it is also likely that miR- 146a disrupts periodontal tissue repair and 
regeneration induced by both epidermal growth factor receptor and 
transforming growth factor beta.33,34
5  | CONCLUSION
Taken together, our results demonstrate that there is an association 
between miR- 146a and GAgP and suggest that miR- 146a may serve 
as an indicator of disease severity. However, more robust studies 
and studies with longitudinal design are required to clarify this as-
sociation and the precise role of miR- 146a in the development and/
or progression of periodontitis.
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